Dynamics of Prostate-Specific Antigen Levels During Treatment with Testosterone Undecanoate in Patients with Type 2 Diabetes Mellitus

Open access


Objectives. Prostate-specific antigen (PSA) is the most used and validated marker of prostate cancer risk. The aim of this study was to assess PSA levels during treatment with testosteronum undecanoat in patients with type 2 diabetes (T2DM). Material and Methods. We evaluated 38 T2DM patients aged between 48 and 61 years with confirmed hypogonadism. 1000 mg testosterone undecanoate was injected intramuscular every 10 to 14 weeks. Total testosterone and PSA levels were assessed at baseline and after 6, 12, 24 months of treatment. Results. The average age was 55.03 ± 2.40 years and 3 patients (7.89%) had a family history of prostate cancer. Treatment with testosterone undecanoate generated significant changes in serum total testosterone (482.29±50.78 ng/dl vs. 246.66±51.50 ng/dl, p < 0.001) but not in serum PSA levels (2.11±.0.49 ng/ml vs. 2.09±0.47 ng/ml, p - NS). Conclusion. Testosterone replacement therapy may normalize serum androgen levels but appears to have little effect on PSA levels.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1. Crawford ED Abrahamsson PA. PSA-based screening for prostate cancer: how does it compare with other cancer screening tests? Eur Urol 54: 262-273 2008.

  • 2. Heinlein CA Chang C. Androgen receptor in prostate cancer. Endocr Rev 25: 276-308 2004.

  • 3. Denmeade SR Lin XS Isaacs JT. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate 28: 251-265 1996.

  • 4. Velcheti V Karnik S Bardot SF Prakash O. Pathogenesis of prostate cancer: lessons from basic research. Ochsner J 8: 213-218 2008.

  • 5. Yuen MT Leung LK Wang J Wong YC Chan FL. Enhanced induction of prostatic dysplasia and carcinoma in Noble rat model by combination of neonatal estrogen exposure and hormonal treatments at adulthood. Int J Oncol 27: 1685-1695 2005.

  • 6. Webber MM Bello D Quader S. Immortalized and tumorigenic adult human prostatic epithelial cell lines: characteristics and applications Part 2. Tumorigenic cell lines. Prostate 30: 58-64 1997.

  • 7. Stanworth RD Jones TH. Testosterone in obesity metabolic syndrome and type 2 diabetes. Front Horm Res 37: 74-90 2009.

  • 8. Stanworth RD Kapoor D Channer KS Jones TH. Statin therapy is associated with lower total but not bioavailable or free testosterone in men with type 2 diabetes. Diabetes Care 32: 541-546 2009

  • 9. Curran MJ Bihrle W 3rd. Dramatic rise in prostate-specific antigen after androgen replacement in a hypogonadal man with occult adenocarcinoma of the prostate. Urology 53: 423-424 1999.

  • 10. Loughlin KR Richie JP. Prostate cancer after exogenous testosterone treatment for impotence. J Urol 157: 1845 1997.

  • 11. Stattin P Lumme S Tenkanen L et al. High levels of circulating testosterone are not associated with increased prostate cancer risk: a pooled prospective study. Int J Cancer: 108: 418-424 2004.

  • 12. Fukui M Tanaka M Kadono M et al. Serum prostate-specific antigen levels in men with type 2 diabetes. Diabetes Care 31: 930-931 2008

  • 13. Dhindsa S Prabhakar S Sethi M Bandyopadhyay A Chaudhuri A Dandona P. Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes J Clin Endocrinol Metab 89: 5462-5468 2004.

  • 14. Dandona P Dhindsa S. Update: Hypogonadotropic hypogonadism in type 2 diabetes and obesity. J Clin Endocrinol Metab 96: 2643-2651 2011.

  • 15. Bassil N Alkaade S Morley JE. The benefits and risks of testosterone replacement therapy: a review. Ther Clin Risk Manag 5: 427-448 2009.

  • 16. Moisey R Swinburne J Orme S. Serum testosterone and bioavailable testosterone correlate with age and body size in hypogonadal men treated with testosterone undecanoate (1000 mg IM--Nebido). Clin Endocrinol (Oxf) 69: 642-647 2008.

  • 17. Wang C Nieschlag E Swerdloff R et al. Investigation treatment and monitoring of late-onset hypogonadism in males: ISA ISSAM EAU EAA and ASA recommendations. Eur J Endocrinol 159: 507-514 2008.

  • 18. Endogenous Hormones and Prostate Cancer Collaborative Group Roddam AW Allen NE Appleby P Key TJ. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst 100: 170-183 2008.

  • 19. Carpenter WR Robinson WR Godley PA. Getting over testosterone: postulating a fresh start for etiologic studies of prostate cancer. J Natl Cancer Inst 100: 158-159 2008.

  • 20. Fernandez-Balsells MM Murad MH Lane M et al. Clinical review 1: Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrin Metab 95: 2560-2575 2010.

  • 21. Rhoden EL Morgentaler A. Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia. J Urol 170: 2348-2351 2003.

  • 22. Douglas TH Connelly RR McLeod DG Erickson SJ Barren R Murphy GP. Effect of exogenous testosterone replacement on prostate-specific antigen and prostate-specific membrane antigen levels in hypogonadal men. J Surg Oncol 59: 246-250 1995.

  • 23. Gooren LJ. A ten-year safety study of the oral androgen testosterone undecanoate. J Androl 15: 212 - 215 1994.

  • 24. Bhasin S Cunningham GR Hayes FJ et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 95: 2536-2559 2010.

  • 25. Bhasin S Singh AB Mac RP Carter B Lee MI Cunningham GR. Managing the risks of prostate disease during testosterone replacement therapy in older men: recommendations for a standardized monitoring plan. J Androl 24: 299-311 2003.

Journal information
Impact Factor

CiteScore 2018: 0.19

SCImago Journal Rank (SJR) 2018: 0.128
Source Normalized Impact per Paper (SNIP) 2018: 0.229

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 146 72 3
PDF Downloads 82 54 2